Dynavax Technologies Corporation (NASDAQ:DVAX) Receives Average Recommendation of “Hold” from Analysts

Shares of Dynavax Technologies Corporation (NASDAQ:DVAX) have earned a consensus recommendation of “Hold” from the five research firms that are currently covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a sell recommendation and three have given a buy recommendation to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $24.3333.

Several equities analysts have recently commented on DVAX shares. Wall Street Zen raised Dynavax Technologies from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. JMP Securities restated a “market outperform” rating and issued a $32.00 price objective on shares of Dynavax Technologies in a report on Friday, August 22nd. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Dynavax Technologies in a research report on Wednesday, October 8th.

Institutional Trading of Dynavax Technologies

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. CIBC Bancorp USA Inc. acquired a new position in Dynavax Technologies during the third quarter worth $109,000. Jacobs Levy Equity Management Inc. grew its stake in shares of Dynavax Technologies by 1.4% in the third quarter. Jacobs Levy Equity Management Inc. now owns 118,484 shares of the biopharmaceutical company’s stock valued at $1,177,000 after buying an additional 1,610 shares in the last quarter. Verition Fund Management LLC raised its holdings in shares of Dynavax Technologies by 841.4% in the 3rd quarter. Verition Fund Management LLC now owns 164,458 shares of the biopharmaceutical company’s stock valued at $1,633,000 after buying an additional 146,988 shares during the period. Qube Research & Technologies Ltd raised its holdings in shares of Dynavax Technologies by 163.0% in the 3rd quarter. Qube Research & Technologies Ltd now owns 754,041 shares of the biopharmaceutical company’s stock valued at $7,488,000 after buying an additional 467,369 shares during the period. Finally, Parkman Healthcare Partners LLC lifted its stake in Dynavax Technologies by 0.4% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 271,306 shares of the biopharmaceutical company’s stock worth $2,694,000 after acquiring an additional 1,175 shares in the last quarter. Hedge funds and other institutional investors own 96.96% of the company’s stock.

Dynavax Technologies Trading Down 0.5%

Shares of DVAX stock opened at $11.37 on Friday. The company has a current ratio of 6.65, a quick ratio of 6.01 and a debt-to-equity ratio of 0.45. Dynavax Technologies has a twelve month low of $9.20 and a twelve month high of $14.63. The company’s 50-day moving average price is $10.45 and its 200-day moving average price is $10.34. The stock has a market cap of $1.34 billion, a price-to-earnings ratio of -24.72 and a beta of 1.09.

Dynavax Technologies (NASDAQ:DVAX) last issued its earnings results on Wednesday, November 5th. The biopharmaceutical company reported $0.21 EPS for the quarter, topping analysts’ consensus estimates of $0.14 by $0.07. The company had revenue of $94.88 million for the quarter, compared to the consensus estimate of $94.00 million. Dynavax Technologies had a negative net margin of 16.67% and a positive return on equity of 5.10%. As a group, equities analysts predict that Dynavax Technologies will post 0.32 earnings per share for the current year.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.